Bcl-xL Antibody (7B2.5)

Flow Cytometry: Bcl-xL Antibody (7B2.5) [NBP1-28559] - Human T cell leukemia cell line Jurkat was intracellularly stained with Mouse Anti-Human Bcl-xL-FITC (NBP1-28560).

Flow Cytometry: Bcl-Xl Antibody (7B2.5) [NBP1-28559] - Bcl-Xl Antibody (7B2.5) 2 ug/10^6 Murine FL5 cells (FL5-NEO) and FL5 cells transfected with Bcl-xL expression plasmid (FL5-BCL-XL) were fixed with buffered paraformaldehyde and then permeabilized with saponin. The cells were incubated with mouse anti-human Bcl-xL followed by phycoerythrin-conjugated goat anti-mouse IgG, and then were analyzed by flow cytometry.

Flow Cytometry: Bcl-xL Antibody (7B2.5) [NBP1-28559] - T Cell leukemia dell line Jurkat was intracellularly stained with Mouse Anti-Human.

• Reactivity: Hu, Mu, Rt, RM
• Applications: WB, Flow, IP
• Clone: 7B2.5
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: 0.1 mg/ml

Bcl-xL Antibody (7B2.5) Summary

• Immunogen: Recombinant human Bcl-xS
• Specificity: Human/Mouse/Rat/Rhesus Bcl-xL
• Isotype: IgG3 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: BCL2L1
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry < = 3 ug/10^6 cells
  • Immunoprecipitation 1:10-1:500
  • Western Blot
• Application Notes: Use in WB reported in scientific literature (PMID:33353284). IP reactivity reported in (PMID: 26939706).

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: BBS (pH 8.2)
• Preservative: No Preservative
• Concentration: 0.1 mg/ml
• Purity: Protein A or G purified

Alternate Names for Bcl-xL Antibody (7B2.5)

• Apoptosis regulator Bcl-X
• bcl2-L-1
• BCL2-like 1
• bcl-2-like protein 1
• BCLXBCL2LBcl-X
• BclxL
• Bcl-xL
• BCL-XL/S
• BCLXS
• bcl-xS
• DKFZp781P2092

Background

Apoptosis, or programmed cell death, is a well-documented phenomenon in many cellular systems. (1) It plays a key role in tissue and organ development as well as in adult tissues during cell turnover. Apoptosis can be induced by a variety of internal and external stimuli including growth factor deprivation, cytokine treatment, antigen-receptor engagement, cell-cell interactions, irradiation and glucocorticoid treatment. (2) Bcl-2 and one of its homologues, Bcl-xL, protect cells from apoptosis (3,4), while other homologues of Bcl-2 such as Bax, Bad and Bak have been shown to enhance apoptosis. (5-8) Bcl-xL has been shown to block apoptosis which is induced by a variety of stimuli and, under certain conditions, offers greater protection against apoptosis than Bcl-2. (9-13) In contrast, Bad and Bax inhibit the protective functions of Bcl-xL and Bcl-2, respectively. Although heterodimerization between Bcl-xL/Bad and Bcl-2/Bax was originally thought to be essential for the differential anti-apoptotic activity of Bcl-xL and Bcl-2, (5,14) other results suggest that the formation of heterodimers may not be necessary for this death-repressing activity. (15,16) Mab 7B2.5 recognizes both human and rodent Bcl-xL. (17)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Bcl-xL Antibody (NBP1-28559)(2)

Publications using NBP1-28559

• Carter BZ, Mak PY, Tao W et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition Haematologica 2020-12-23 [PMID: 33353284] (WB, Human)
• Punnoose E, Leverson JD, Peale F et al. Expression profile of BCL-2, BCL-XL and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models Mol. Cancer Ther [PMID: 26939706] (IP, Human)
  
  Details:
  Used the Biotin form of this antibody.

Bioinformatics

• Gene Symbol: BCL2L1